OXC-101 as a novel therapy in canine blood cancer will be presented at AACR

In a collaboration with SLU and Karolinska Institutet, Oxcia’s mitotic MTH1 inhibitor OXC-101 is investigated in a pilot clinical study in canine lymphoma and hemangiosarcoma. The early clinical results are presented by Dr. Kumar Sanjiv at the American Association for Cancer Research (AACR) annual meeting 19-22 April, 2026. The title of the presentation is: “OXC-2101 (karonudib) in canine lymphoma and hemangiosarcoma: Safety, early efficacy and translational potential” (Poster Number 7913) and will be presented Wed 22 April 2026.

For more information contact:

Ulrika Warpman Berglund, CEO, Oxcia AB (publ)

Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com

Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.

More information about Oxcia is available at www.oxcia.com